Free Trial
OTCMKTS:EVTCY

Evotec (EVTCY) Stock Price, News & Analysis

Evotec logo
$4.73 +0.70 (+17.37%)
As of 05/23/2025

About Evotec Stock (OTCMKTS:EVTCY)

Key Stats

Today's Range
$4.58
$4.80
50-Day Range
$2.97
$4.30
52-Week Range
$14.22
$26.57
Volume
530,778 shs
Average Volume
2,407 shs
Market Capitalization
$1.56 billion
P/E Ratio
11.54
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVTCY Stock News Headlines

Volatility Is Rising—But These 2 AI Stocks Could Thrive
2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines. But even in uncertain times, innovation doesn’t slow down. In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles. Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar.
See More Headlines

EVTCY Stock Analysis - Frequently Asked Questions

Evotec's stock was trading at $4.16 at the beginning of 2025. Since then, EVTCY stock has increased by 13.7% and is now trading at $4.73.
View the best growth stocks for 2025 here
.

Evotec's stock split on Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly issued shares were distributed to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Evotec subsidiaries include these companies: Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and more.

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
5/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:EVTCY
Employees
4,200
Year Founded
1993

Profitability

Trailing P/E Ratio
11.54
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$7.14 million
Pretax Margin
23.90%

Debt

Sales & Book Value

Annual Sales
$572.16 million
Cash Flow
$0.04 per share
Price / Cash Flow
105.53
Book Value
$2.52 per share
Price / Book
1.88

Miscellaneous

Free Float
N/A
Market Cap
$1.56 billion
Optionable
Not Optionable
Beta
0.98

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:EVTCY) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners